The Phase 1b trial is testing ZYNLONTA plus glofitamab in relapsed or refractory diffuse large B-cell lymphoma, with full data expected in the fourth quarter of 2026 and publication planned by year-end.
verifying reliability
No specialized terms available for this topic.